Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
Recruiting · NCT06474169 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centre Hospitalier Régional d'Orléans
View the official record on ClinicalTrials.gov →Interventions studied
1 blood sample for each participant
What this trial is about
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease. The study population was patients with chronic kidney disease.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Male or female ≥ 18 years
- Informed participants who did not object to participating in the study
Exclusion criteria
- Chronic progressive infections
- Prior organ transplantation (including bone marrow transplantation)
- Previous treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus or Ciclosporin, Cellcept or Imurel) within 2 years prior to inclusion
- Participant under guardianship, curatorship or deprived of liberty
- Pregnant or breastfeeding women
Where it is running
1 location listed.
- Center Hospitalier Universitaire d'Orléans - Orléans, France